Glatiramer Acetate Depot Injection Shows T1 and T2 Lesion Reduction in Relapsing MSFebruary 24th 2023
Secondary findings from a phase 3 study demonstrate a significant decrease in new T1 enhancing lesions and new enlarging hyperintense T2 lesions in patients with multiple sclerosis undergoing glatiramer acetate depot treatment.
The Mount Sinai Perspective on the State of MS Care: Stephen Krieger, MDAugust 5th 2022
The neurologist at the Corinne Goldsmith Dickinson Center for MS offered an overview of the State of the Science Summit that was held on June 30, 2022, with a variety of expert clinicians from Mount Sinai. [WATCH TIME: 7 minutes]
The Future of Care and Focusing on Brain Health in MS to Maximize ReserveMay 30th 2022
Stephen Krieger, MD, of the Icahn School of Medicine and Corinne Goldsmith Dickinson Center for MS at Mount Sinai, shared his perspectives on the trends in multiple sclerosis and the need to holistically treat patients to maximize brain reserve.
An AI Morphology Array’s Potential to Improve Parkinson DiagnosisMay 13th 2022
John F. Crary, MD, PhD, and Jerry Fernandez, MD, offer insight into PreciseDx's AI Morphology Feature Array and how this technology can improve neuropathology and diagnosis for neurodegenerative diseases, such as Parkinson disease.
The Future of Digital Neuropathology and the Role of AI: John F. Crary, MD, PhD; Gerardo Fernandez, MDMay 6th 2022
The neuropathologist at Mount Sinai and chief science officer of Precise Dx pairing spoke to the role of artificial intelligence in the diagnosis of diseases from peripheral tissue biopsies and its ability to improve neuropathology. [WATCH TIME: 8 minutes]
PreciseDx's AI Morphology Feature Array for Detecting Parkinson Disease Pathology: John F. Crary, MD, PhD; Gerardo Fernandez, MDMay 5th 2022
The neuropathologist at Mount Sinai and chief science officer of Precise Dx pairing shared background information on the artificial intelligence’s ability to improve the diagnosis of Parkinson disease from peripheral tissue biopsies. [WATCH TIME: 9 minutes]
Combination Agent P2B001 Shows Promise for Parkinson Disease in Phase 3 DataApril 5th 2022
The Pharma Two B therapy combines a dopamine agonist, pramipexole, and an MAO-B inhibitor, rasagiline, and has shown significant improvements on UPDRS total scores and ESS scores for untreated patients with PD.
Exciting Multiple Sclerosis Debates at IFN 2021: Fred Lublin, MDAugust 13th 2021
The director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center spoke on what he is looking forward to at the 2021 International Congress on the Future of Neurology.